期刊文献+

肺动脉高压分类、发病机制及治疗 被引量:1

Classification and pathogensis and treatment of pulmonary arterial hypertension
原文传递
导出
摘要 肺动脉高压(pulmonary arterial hypertension,PAH)是由多种病冈引起并有复杂发病机制的疾病。表现为肺循环的压力和阻力的增加,最终导致右心衰竭,治疗棘手。近年来,PAH的诊断、分类不断更新、完善;发病机制、病理生理、分子生物学的研究不断深入;临床治疗药物也在不断探索。为PAH的诊治开拓了广阔的前景。本文复习文献,对目前PAH研究现状及进展进行阐述。 Pulmonary arterial hypertension (PAH) is a disease by variety of causes, and its pathogensis is complex. In which pulmonary arterial obstruction increases pulmonary vascular resistance, which leads to right ventricular failure, the therapy troublesome. In recent years, The diagnosis and classification of PAH was updated, with deeply researching on the pathogcnsis, pathophysiology and molecular biology, The treatment is researching constantly. To provide a wide prospect for PAH and diagnosis. This article reviews literature, to explain the recent advances on PAH.
出处 《国际呼吸杂志》 2011年第20期1590-1593,共4页 International Journal of Respiration
基金 云南省教育厅科学研究基金项目(2010C091) 国家自然科学基金项目(81100037)
关键词 肺动脉高压 诊断 分类 发病机制 治疗 Pulmonary arterial hypertension Diagnosis Classification Pathogensis Treatment
  • 相关文献

参考文献18

  • 1Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest, 2007, 131 : 1917 1928.
  • 2Task Force {or Diagnosis and Treatment of PulmonaryHypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS) ; International Society of Heart and Lung Transplantation (ISHLT), et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J, 2009,34 : 1219-1263.
  • 3Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol, 2009,54 ( 1 Suppl) : S55-S66.
  • 4Sztrymf B, Yaici A, Girerd B, et al. Genes and pulmonary arterial hypertension. Respiration, 2007,74 : 123-132.
  • 5Morse JH, Deng Z, Knowles JA. Genetic aspects of pulmonary arterial hypertension. Ann Med, 2001, 33:596 603.
  • 6Trembath RC, Thomson JR, Machado RD,et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med,2001,345:325 334.
  • 7Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest, 2001,108: 1141-1150.
  • 8Long L, MacLean MR, Jeffery TK,et al. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res,2006,98:818-827.
  • 9Remillard CV, Yuan JX. Activation of. K+ channels= an essential pathway in programmed cell death. Am J Physiol Lung Cell Mol Physiol, 2004,286 : L49 L67.
  • 10Mandegar M, Yuan JX. Role of K+ channels in pulmonary hypertension. Vascul Pharmacol, 2002,38 : 25-33.

同被引文献16

  • 1杨劲松,聂磊,刘一骐.先天性心脏病合并肺动脉高压患者的外科治疗体会[J].中国现代医学杂志,2007,17(16):2018-2020. 被引量:2
  • 2Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart,Lung, and Blood Institute, Primary Pulmonary Hypertension Registry [J]. Circulation, 1989, 80(5): 1198-1206.
  • 3Gali N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension : The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), Endorsed by the International Society of Heart and Lung Transplantation (ISHLT) [J]. Eur Heart J, 2009, 30(20): 2493-2537.
  • 4Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension [ J]. Eur Respir J, 2005, 26 (5) : 858-863.
  • 5Barst RJ. Recent advances in the treatment of pediatric pulmonary artery hypertension [ J]. Peaiat Clin North Amer, 1999, 46 (2) : 331-345.
  • 6兰锡纯,冯卓荣.心脏外科学[M].第2版,北京:人民卫生出版社,2002.
  • 7Ruhin LI. Primary pulmonary [J]. N Engl J Med, 2002, 165 (5) : 1209-1216.
  • 8Schermuly RT, Krupnik E, Tenor H, et al. Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: Maintenance of lumg selectivty [J. Am J Respir Crit Care Med, 2001, 164(9) : 1694-1700.
  • 9Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension [ J]. N Engl J Med, 2005, 353 (20) : 2148-2157.
  • 10Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary arterial hypertension in a large Kindre [ J ]. N Engl J Med, 2001, 345(5): 319-324.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部